Go Pro
NASDAQ:NYXH

Nyxoah Q2 2026 Earnings Report

Nyxoah logo
$1.40 0.00 (0.00%)
Closing price 07/27/2026 04:00 PM Eastern
Extended Trading
$1.40 +0.00 (+0.07%)
As of 07:26 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Nyxoah EPS Results

Actual EPS
N/A
Consensus EPS
-$0.47
Beat/Miss
N/A
One Year Ago EPS
N/A

Nyxoah Revenue Results

Actual Revenue
N/A
Expected Revenue
$8.64 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Nyxoah Announcement Details

Quarter
Q2 2026
Time
Before Market Opens
Conference Call Date
Wednesday, August 5, 2026
Conference Call Time
4:30PM ET

Conference Call Resources

Nyxoah Earnings Headlines

A 50-year dollar arrangement just ended - what it means for you
In 1974, Henry Kissinger helped create the U.S.-Saudi Arabia Joint Commission on Economic Cooperation - a little-known arrangement that tied global oil trade to the U.S. dollar for 50 years. On June 9, 2024, it quietly expired. Garrett Goggin, CFA, CMT, believes this dollar reset could hit stocks, real estate, and retirement accounts hard - with inflation potentially running 10% to 15% for years. He has identified a small group of gold stocks he thinks are positioned to benefit as the dollar system shifts.tc pixel
Nyxoah SA (NYXH) Analyst/Investor Day Transcript
See More Nyxoah Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Nyxoah? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nyxoah and other key companies, straight to your email.

About Nyxoah

Nyxoah (NASDAQ:NYXH), headquartered in Mont-Saint-Guibert, Belgium, is a medical technology company focused on neuromodulation therapies for sleep‐disordered breathing. Established in 2018, the company’s primary offering is the Genio® system, a minimally invasive bilateral hypoglossal nerve stimulator designed to treat moderate to severe obstructive sleep apnea (OSA). By electrically stimulating the genioglossus muscle, the device helps maintain airway patency during sleep, reducing apnea events and improving overall sleep quality.

The Genio system comprises a small, implantable stimulator positioned submentally and an external activation unit worn by the patient. Prior to bedtime, users apply the activation patch, which wirelessly powers the implant and delivers timed electrical pulses to the tongue muscles. Following a CE mark in 2019, Nyxoah initiated commercial launches across Europe and select international markets. The company is actively pursuing additional regulatory clearances, including a premarket application with the U.S. Food and Drug Administration, and is conducting ongoing clinical studies to expand the system’s indications and validate long-term safety and efficacy.

Building on its flagship product, Nyxoah continues to invest in research and development aimed at next-generation neuromodulation platforms for various sleep-related disorders. The company maintains a global footprint with commercial operations in Europe and a subsidiary in the United States, and collaborates with leading sleep centers to drive physician adoption and patient access. Nyxoah’s management team combines expertise in medical devices, sleep medicine, and implantable technologies to advance its mission of improving outcomes for patients suffering from obstructive sleep apnea.

View Nyxoah Profile